Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results
Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination. Methods: We reviewed all the pu...
Uloženo v:
| Vydáno v: | Frontiers in immunology Ročník 12; s. 657711 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
Frontiers Media S.A
12.03.2021
|
| Témata: | |
| ISSN: | 1664-3224, 1664-3224 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background:
BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination.
Methods:
We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided.
Results:
BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a T
H
1 response and no evidence of vaccine-enhanced disease have been reported.
Discussion:
BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited. |
|---|---|
| AbstractList | BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination.
We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided.
BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a T
1 response and no evidence of vaccine-enhanced disease have been reported.
BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited. Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination. Methods: We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided. Results: BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a TH1 response and no evidence of vaccine-enhanced disease have been reported. Discussion: BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited. Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination. Methods: We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided. Results: BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a TH1 response and no evidence of vaccine-enhanced disease have been reported. Discussion: BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited.Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination. Methods: We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided. Results: BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a TH1 response and no evidence of vaccine-enhanced disease have been reported. Discussion: BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited. Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination. Methods: We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided. Results: BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a T H 1 response and no evidence of vaccine-enhanced disease have been reported. Discussion: BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited. |
| Author | Mangioni, Davide Muscatello, Antonio Bandera, Alessandra Bozzi, Giorgio Lombardi, Andrea Gori, Andrea Ungaro, Riccardo Villa, Simone Castelli, Valeria |
| AuthorAffiliation | 3 Center for Multidisciplinary Research in Health Science (MACH), University of Milano , Milan , Italy 1 Infectious Diseases Unit, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico , Milan , Italy 2 Department of Pathophysiology and Transplantation, University of Milano , Milan , Italy |
| AuthorAffiliation_xml | – name: 3 Center for Multidisciplinary Research in Health Science (MACH), University of Milano , Milan , Italy – name: 1 Infectious Diseases Unit, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico , Milan , Italy – name: 2 Department of Pathophysiology and Transplantation, University of Milano , Milan , Italy |
| Author_xml | – sequence: 1 givenname: Andrea surname: Lombardi fullname: Lombardi, Andrea – sequence: 2 givenname: Giorgio surname: Bozzi fullname: Bozzi, Giorgio – sequence: 3 givenname: Riccardo surname: Ungaro fullname: Ungaro, Riccardo – sequence: 4 givenname: Simone surname: Villa fullname: Villa, Simone – sequence: 5 givenname: Valeria surname: Castelli fullname: Castelli, Valeria – sequence: 6 givenname: Davide surname: Mangioni fullname: Mangioni, Davide – sequence: 7 givenname: Antonio surname: Muscatello fullname: Muscatello, Antonio – sequence: 8 givenname: Andrea surname: Gori fullname: Gori, Andrea – sequence: 9 givenname: Alessandra surname: Bandera fullname: Bandera, Alessandra |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33777055$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kk1v1DAQhi1UREvpD-CCcuSSxY7tOOaAVC1fKxWKqqocrVlnvHXl2CVOiuDX4-62qEXCF1vz8bwjz_uc7MUUkZCXjC447_Qb54dhXjS0YYtWKsXYE3LA2lbUvGnE3oP3PjnK-YqWIzTnXD4j-5wrpaiUB2TzxUdfneGNx5_VqhBjCmnjLYRqmWLGHzNGi7lKbpf1v2HyKVbf_XRZLU8vVu9rpqvh7OtxdQHW-oj5bfVtxOAHH2H8VdB5DlN-QZ46CBmP7u5Dcv7xw_nyc31y-mm1PD6prWjlVDvtqHBSI5e9RdZqLa3sHDZKQb-Gru2cBdkKpSRAjw3ttJQU1hapY9bxQ7LaYfsEV-Z69EOZwSTwZhtI48bAOHkb0IATneSqB6SN4F0HgusegDnKQfWUF9a7Het6Xg9YxonTCOER9HEm-kuzSTdGaS2U6Arg9R1gTOUf82QGny2GABHTnE0jaSupZoyV0lcPtf6K3C-qFKhdgR1TziM6Y_20XUWR9sEwam5dYbauMLeuMDtXlE72T-c9_P89fwBAbrzR |
| CitedBy_id | crossref_primary_10_3390_ijms22168988 crossref_primary_10_3892_mmr_2021_12217 crossref_primary_10_3390_vaccines10020154 crossref_primary_10_1186_s12943_023_01807_w crossref_primary_10_3390_vaccines9101207 crossref_primary_10_3390_v14061257 crossref_primary_10_3390_pathogens12121408 crossref_primary_10_7759_cureus_40543 crossref_primary_10_3390_ijerph181910081 crossref_primary_10_1016_j_jiph_2021_07_005 crossref_primary_10_1111_apm_13284 crossref_primary_10_3390_ijms24065944 crossref_primary_10_3390_vaccines10101609 crossref_primary_10_1002_jmv_27572 crossref_primary_10_3390_vaccines11020281 crossref_primary_10_1016_j_mehy_2022_110965 crossref_primary_10_1590_1806_9282_20220620 crossref_primary_10_2174_0113816128280417231204085137 crossref_primary_10_3390_vaccines9040316 crossref_primary_10_1002_rmv_2451 crossref_primary_10_1016_j_jcv_2021_105024 crossref_primary_10_1016_j_anai_2021_05_015 crossref_primary_10_3390_medicina59020272 crossref_primary_10_1039_D5TB00630A crossref_primary_10_1111_tmi_13869 crossref_primary_10_3390_vaccines9101151 crossref_primary_10_1371_journal_pone_0259731 crossref_primary_10_1186_s12879_022_07083_1 crossref_primary_10_3390_diagnostics12061315 crossref_primary_10_1155_2021_6806500 crossref_primary_10_3389_fimmu_2021_679344 crossref_primary_10_3390_vaccines10040552 crossref_primary_10_1016_j_vaccine_2021_10_068 crossref_primary_10_1093_ndt_gfab241 crossref_primary_10_3390_v13101911 crossref_primary_10_1038_s41541_022_00485_x |
| Cites_doi | 10.1016/j.celrep.2021.108699 10.1016/j.blre.2015.10.001 10.1056/NEJMoa2024671 10.1101/2020.09.08.280818 10.1056/NEJMoa2022483 10.1038/nrd.2017.243 10.1056/NEJMoa2034577 10.1038/s41586-020-2622-0 10.1056/NEJMoa2027906 10.1038/s41563-020-0746-0 10.1038/s41467-020-20247-4 10.3389/fcimb.2020.572681 10.1056/NEJMc2032195 10.1038/s41586-020-2550-z 10.1038/s41591-021-01270-4 10.1056/NEJMoa2035389 10.1038/s41564-020-00789-5 10.1155/2015/794528 10.1038/s41586-020-2639-4 10.1038/s41586-020-2814-7 10.1038/s41586-020-2798-3 10.1126/science.abb8923 10.1038/s41564-020-00813-8 10.1056/NEJMoa2028436 10.1038/s41586-020-03041-6 10.1038/s41467-020-18450-4 |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 Lombardi, Bozzi, Ungaro, Villa, Castelli, Mangioni, Muscatello, Gori and Bandera. Copyright © 2021 Lombardi, Bozzi, Ungaro, Villa, Castelli, Mangioni, Muscatello, Gori and Bandera. 2021 Lombardi, Bozzi, Ungaro, Villa, Castelli, Mangioni, Muscatello, Gori and Bandera |
| Copyright_xml | – notice: Copyright © 2021 Lombardi, Bozzi, Ungaro, Villa, Castelli, Mangioni, Muscatello, Gori and Bandera. – notice: Copyright © 2021 Lombardi, Bozzi, Ungaro, Villa, Castelli, Mangioni, Muscatello, Gori and Bandera. 2021 Lombardi, Bozzi, Ungaro, Villa, Castelli, Mangioni, Muscatello, Gori and Bandera |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3389/fimmu.2021.657711 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-3224 |
| ExternalDocumentID | oai_doaj_org_article_af48537dae024388a439daa1f03a7d03 PMC7994748 33777055 10_3389_fimmu_2021_657711 |
| Genre | Journal Article Review |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM ACXDI CGR CUY CVF ECM EIF IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c465t-f9f04f59e35dce16995c58fe277adba868fca564775aade2089550abce0f1cf3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 46 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000632854200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1664-3224 |
| IngestDate | Fri Oct 03 12:52:48 EDT 2025 Tue Sep 30 15:58:39 EDT 2025 Fri Sep 05 10:42:08 EDT 2025 Thu Apr 03 07:05:51 EDT 2025 Sat Nov 29 02:49:02 EST 2025 Tue Nov 18 22:13:35 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 SARS-CoV-2 CTL antibodies RNA vaccine neutralization test |
| Language | English |
| License | Copyright © 2021 Lombardi, Bozzi, Ungaro, Villa, Castelli, Mangioni, Muscatello, Gori and Bandera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c465t-f9f04f59e35dce16995c58fe277adba868fca564775aade2089550abce0f1cf3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Edited by: Gene S. Tan, J. Craig Venter Institute (La Jolla), United States This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology Reviewed by: Sang-Moo Kang, Georgia State University, United States; Salvador Iborra, Universidad Complutense de Madrid, Spain |
| OpenAccessLink | https://doaj.org/article/af48537dae024388a439daa1f03a7d03 |
| PMID | 33777055 |
| PQID | 2506509111 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_af48537dae024388a439daa1f03a7d03 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7994748 proquest_miscellaneous_2506509111 pubmed_primary_33777055 crossref_citationtrail_10_3389_fimmu_2021_657711 crossref_primary_10_3389_fimmu_2021_657711 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-03-12 |
| PublicationDateYYYYMMDD | 2021-03-12 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in immunology |
| PublicationTitleAlternate | Front Immunol |
| PublicationYear | 2021 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | B22 Seow (B6) 2020; 5 Le Bert (B5) 2020; 584 Lau (B7) 2021; 12 B27 B28 Anderson (B13) 2020; 383 Lee (B31) 2020; 5 Widge (B14) 2021; 384 Tsigrelis (B30) 2016; 30 McNamara (B29) 2015; 2015 Corbett (B24) 2020; 586 Polack (B20) 2020; 383 Baden (B26) 2020; 384 Walsh (B10) 2020; 383 Huang (B4) 2020; 11 Corbett (B25) 2020; 383 Marsden (B3) 2020 Vogel (B19) 2020 Zhou (B34) 2021; 34 Shukla (B33) 2020; 10 (B23) 2021 Graham (B32) 2020; 368 B18 Jackson (B12) 2020; 383 (B17) 2020 B1 Sahin (B11) 2020; 586 van Riel (B16) 2020; 19 Xie (B21) 2021 McMahan (B2) 2020; 590 Krammer (B8) 2020; 586 Mulligan (B9) 2020; 586 Pardi (B15) 2018; 17 |
| References_xml | – volume: 34 start-page: 108699 year: 2021 ident: B34 article-title: Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD publication-title: Cell Rep. doi: 10.1016/j.celrep.2021.108699 – volume: 30 start-page: 139 year: 2016 ident: B30 article-title: Vaccinations in patients with hematological malignancies publication-title: Blood Rev. doi: 10.1016/j.blre.2015.10.001 – volume: 383 start-page: 1544 year: 2020 ident: B25 article-title: Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates publication-title: N Engl J Med. doi: 10.1056/NEJMoa2024671 – volume-title: bioRxiv [Preprint]. year: 2020 ident: B19 article-title: A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates doi: 10.1101/2020.09.08.280818 – volume: 383 start-page: 1920 year: 2020 ident: B12 article-title: An mRNA vaccine against SARS-CoV-2 - preliminary report publication-title: N Engl J Med. doi: 10.1056/NEJMoa2022483 – volume: 17 start-page: 261 year: 2018 ident: B15 article-title: mRNA vaccines-a new era in vaccinology publication-title: Nat Rev Drug Discov. doi: 10.1038/nrd.2017.243 – volume: 383 start-page: 2603 year: 2020 ident: B20 article-title: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine publication-title: N Engl J Med. doi: 10.1056/NEJMoa2034577 – volume: 586 start-page: 567 year: 2020 ident: B24 article-title: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness publication-title: Nature. doi: 10.1038/s41586-020-2622-0 – volume: 383 start-page: 2439 year: 2020 ident: B10 article-title: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates publication-title: N Engl J Med. doi: 10.1056/NEJMoa2027906 – ident: B1 – volume: 19 start-page: 810 year: 2020 ident: B16 article-title: Next-generation vaccine platforms for COVID-19 publication-title: Nat Mater. doi: 10.1038/s41563-020-0746-0 – ident: B27 – volume: 12 start-page: 1 year: 2021 ident: B7 article-title: Neutralizing antibody titres in SARS-CoV-2 infections publication-title: Nat Commun. doi: 10.1038/s41467-020-20247-4 – start-page: 1 volume-title: Comirnaty: SUMMARY OF PRODUCT CHARACTERISTICS. ident: B18 – volume: 10 start-page: 572681 year: 2020 ident: B33 article-title: Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine publication-title: Front Cell Infect Microbiol. doi: 10.3389/fcimb.2020.572681 – volume: 384 start-page: 80 year: 2021 ident: B14 article-title: Durability of responses after SARS-CoV-2 mRNA-1273 vaccination publication-title: N Engl J Med. doi: 10.1056/NEJMc2032195 – volume: 584 start-page: 457 year: 2020 ident: B5 article-title: SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls publication-title: Nature. doi: 10.1038/s41586-020-2550-z – year: 2021 ident: B21 article-title: Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera publication-title: Nat Med. doi: 10.1038/s41591-021-01270-4 – volume: 384 start-page: 403 year: 2020 ident: B26 article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine publication-title: N Engl J Med. doi: 10.1056/NEJMoa2035389 – volume: 5 start-page: 1185 year: 2020 ident: B31 article-title: Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies publication-title: Nat Microbiol. doi: 10.1038/s41564-020-00789-5 – volume: 2015 start-page: 1 year: 2015 ident: B29 article-title: RNA-based vaccines in cancer immunotherapy publication-title: J Immunol Res. doi: 10.1155/2015/794528 – volume: 586 start-page: 589 year: 2020 ident: B9 article-title: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults publication-title: Nature. doi: 10.1038/s41586-020-2639-4 – volume: 586 start-page: 594 year: 2020 ident: B11 article-title: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses publication-title: Nature. doi: 10.1038/s41586-020-2814-7 – volume: 586 start-page: 516 year: 2020 ident: B8 article-title: SARS-CoV-2 vaccines in development publication-title: Nature. doi: 10.1038/s41586-020-2798-3 – volume: 368 start-page: 945 year: 2020 ident: B32 article-title: Rapid COVID-19 vaccine development publication-title: Science. doi: 10.1126/science.abb8923 – volume: 5 start-page: 1598 year: 2020 ident: B6 article-title: Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans publication-title: Nat Microbiol. doi: 10.1038/s41564-020-00813-8 – volume: 383 start-page: 2427 year: 2020 ident: B13 article-title: Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults publication-title: N Engl J Med. doi: 10.1056/NEJMoa2028436 – ident: B28 – ident: B22 – volume: 590 start-page: 630 year: 2020 ident: B2 article-title: Correlates of protection against SARS-CoV-2 in rhesus macaques publication-title: Nature doi: 10.1038/s41586-020-03041-6 – start-page: 1 year: 2020 ident: B3 article-title: Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers publication-title: N Engl J Med. – volume: 11 start-page: 1 year: 2020 ident: B4 article-title: A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity publication-title: Nat Commun. doi: 10.1038/s41467-020-18450-4 – start-page: 1 volume-title: COVID-19 Vaccine Moderna: SUMMARY OF PRODUCT CHARACTERISTICS year: 2021 ident: B23 – volume-title: Comirnaty (COVID-19 mRNA Vaccine [Nucleoside Modified]) year: 2020 ident: B17 |
| SSID | ssj0000493335 |
| Score | 2.4860232 |
| SecondaryResourceType | review_article |
| Snippet | Background:
BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy.... BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about... Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy.... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 657711 |
| SubjectTerms | 2019-nCoV Vaccine mRNA-1273 Animals antibodies Antibodies, Neutralizing - blood Antibodies, Viral - blood BNT162 Vaccine COVID-19 COVID-19 - blood COVID-19 - immunology COVID-19 - prevention & control COVID-19 - virology COVID-19 Vaccines - adverse effects COVID-19 Vaccines - therapeutic use CTL Diffusion of Innovation Host-Pathogen Interactions Humans Immunization Immunogenicity, Vaccine Immunology mRNA Vaccines neutralization test RNA vaccine SARS-CoV-2 SARS-CoV-2 - genetics SARS-CoV-2 - immunology Treatment Outcome Vaccines, Synthetic - adverse effects Vaccines, Synthetic - therapeutic use |
| Title | Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33777055 https://www.proquest.com/docview/2506509111 https://pubmed.ncbi.nlm.nih.gov/PMC7994748 https://doaj.org/article/af48537dae024388a439daa1f03a7d03 |
| Volume | 12 |
| WOSCitedRecordID | wos000632854200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-3224 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000493335 issn: 1664-3224 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9MwFLfGNCQuaHx3g8mTOCGFxXEc29xG2cQO6yY0jd4sxx8sqE2nJp20y_52_OK0ahGCC5ccYid2_HvOe89-_j2E3lNXelEUJhHCZEkurEi0tDShjlKgK6M2s12yCT4aifFYXq6l-oKYsEgPHAfuSPs8aBRutQPuPCF00KBWa-JTqrmNPJ8pl2vO1M9o91JKWdzGDF6YPPLVdLoI_mBGPhaMc0I2FFHH1_8nI_P3WMk15XO6i572ViM-jr19hrZc_Rw9jnkk71-gH-dVXeG4zI_P4MTH8peGh2vR0njmY2l_9hJ_r9obPLy4PvuSEImn30bH-Fob2GpvPuHLuZt0Kb_m9-HVzWLSNi_R1enJ1fBr0mdQSExesDbx0qe5Z9JRFj6AFFIyw4R3GefalloUwhvN4Cwq09q6LBUyeCy6NC71xHj6Cm3Xs9q9Qbg0we4JcKfCy9xbL1yw1IJtxQKyhJV6gNLlaCrTs4tDkouJCl4GAKA6ABQAoCIAA_Rh9chtpNb4W-XPANGqIrBidzeCrKheVtS_ZGWADpcAqzCLYGtE1262aFQwBIFKkEBDryPgq6ZAaIFzaID4hihs9GWzpK5uOqZuLmXOc7H3Pzq_j57AeED8G8neou12vnDv0I65a6tmfoAe8bE46CZBuJ4_nPwCSAkObg |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mini+Review+Immunological+Consequences+of+Immunization+With+COVID-19+mRNA+Vaccines%3A+Preliminary+Results&rft.jtitle=Frontiers+in+immunology&rft.au=Lombardi%2C+Andrea&rft.au=Bozzi%2C+Giorgio&rft.au=Ungaro%2C+Riccardo&rft.au=Villa%2C+Simone&rft.date=2021-03-12&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=12&rft_id=info:doi/10.3389%2Ffimmu.2021.657711&rft_id=info%3Apmid%2F33777055&rft.externalDocID=PMC7994748 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |